Trial Profile

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 06753512 (Primary) ; PF 6755990 (Primary) ; PF 6755992 (Primary) ; Sasanlimab (Primary) ; Tremelimumab (Primary)
Indications Prostate cancer
Focus Adverse reactions; First in man
Acronyms PrCa VBIR
Sponsors Pfizer

Most Recent Events

02 Dec 2021 Status changed from completed to discontinued.
08 Jun 2021 Results assessing safety and efficacy of PF-06753512 in patients with biochemical relapse and metastatic castration-resistant prostate cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
05 Mar 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com